Elaine Paul

Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918

C.M.F. Kruijtzer, Jos H. Beijnen, Hilde Rosing et al. · Journal of Clinical Oncology · 2002 · 462 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients

I. E. L. M. Kuppens, Els O. Witteveen, Roxanne C. Jewell et al. · Clinical Cancer Research · 2007 · 176 citations

Medicine, Oncology, Pharmacology +16

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

Mirte M. Malingré, Jos H. Beijnen, Hilde Rosing et al. · British Journal of Cancer · 2001 · 151 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer

Anna Maria Storniolo, Mark D. Pegram, Beth Overmoyer et al. · Journal of Clinical Oncology · 2008 · 119 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors

A. S. T. Planting, Pieter Sonneveld, Ate van der Gaast et al. · Cancer Chemotherapy and Pharmacology · 2004 · 106 citations

Medicine, Oncology, Pharmacology +10